drugset
drugset / Trial / NCT05288673

A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants

NCT05288673 ↗

Phase 1 Completed 16 enrolled Alexion Pharmaceuticals, Inc.
RandomizedSequentialTriple-blindBasic science

Summary

This study evaluated the safety and tolerability of multiple doses of ALXN1210 (400 and 800 milligrams \[mg\]) following intravenous (IV) administration to healthy participants.

Timeline

Start
2015-07-28
Primary completion
2016-09-01
Completion
2016-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravulizumab Monoclonal antibody 400 mg Intravenous
Subject Ravulizumab Monoclonal antibody 800 mg Intravenous

Indications

No indication recorded.